Barclays PLC Has $4.28 Million Stock Holdings in Surmodics, Inc. (NASDAQ:SRDX)

Barclays PLC grew its stake in shares of Surmodics, Inc. (NASDAQ:SRDX - Free Report) by 21.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 108,001 shares of the company's stock after acquiring an additional 19,251 shares during the quarter. Barclays PLC owned about 0.76% of Surmodics worth $4,278,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. Legal & General Group Plc grew its stake in Surmodics by 34.2% during the fourth quarter. Legal & General Group Plc now owns 3,452 shares of the company's stock worth $137,000 after buying an additional 880 shares in the last quarter. Polymer Capital Management US LLC acquired a new stake in shares of Surmodics during the 4th quarter worth approximately $255,000. Yakira Capital Management Inc. increased its stake in Surmodics by 103.2% in the fourth quarter. Yakira Capital Management Inc. now owns 71,113 shares of the company's stock valued at $2,816,000 after acquiring an additional 36,113 shares during the last quarter. Wells Fargo & Company MN raised its position in Surmodics by 40.9% during the fourth quarter. Wells Fargo & Company MN now owns 7,032 shares of the company's stock valued at $278,000 after purchasing an additional 2,041 shares in the last quarter. Finally, DLD Asset Management LP bought a new stake in Surmodics during the fourth quarter worth $2,514,000. Institutional investors own 96.63% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. StockNews.com began coverage on Surmodics in a report on Monday, February 3rd. They set a "hold" rating for the company. Lake Street Capital raised shares of Surmodics from a "hold" rating to a "buy" rating and set a $43.00 target price for the company in a report on Friday, March 7th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Surmodics in a report on Wednesday. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat, the company has an average rating of "Hold" and an average target price of $52.33.

Surmodics Price Performance

SRDX stock traded down $0.24 during midday trading on Friday, reaching $27.63. 11,882 shares of the stock were exchanged, compared to its average volume of 277,631. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.45 and a quick ratio of 4.29. The stock has a market capitalization of $394.93 million, a PE ratio of -27.56 and a beta of 1.30. Surmodics, Inc. has a 52 week low of $26.00 and a 52 week high of $42.44. The company has a fifty day moving average price of $29.59 and a 200 day moving average price of $34.99.

Surmodics (NASDAQ:SRDX - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.07). Surmodics had a negative net margin of 11.48% and a negative return on equity of 4.39%. The firm had revenue of $28.09 million during the quarter, compared to analyst estimates of $32.23 million. As a group, analysts expect that Surmodics, Inc. will post 0.2 EPS for the current fiscal year.

Surmodics Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).